今月の研究者

森 有紀

森 有紀

キャリア
私は、当初基礎医学に興味があり、大阪大学医学部医科学研究科修士課程の時に大阪大学微生物病研究所で癌抑制遺伝子の研究を開始したのですが、臨床医学への思いが強くなり、千葉大学医学部に入学しました。卒業後、東京大学医学部附属病院での研修を経て同大学血液腫瘍内科に入局しました。がん・研究センター都立駒込病院で血液内科の基礎を学んだ後、大学病院では、臨床業務の傍ら、移植後ウイルス感染症(アデノウイルス、サイトメガロウイルス(CMV)、水痘帯状疱疹ウイルス)に関する臨床研究をスタートしました。2003年に日本赤十字社医療センター血液内科に異動しましたが、臨床研究も継続し、2008年に移植後CMV感染症に関する研究で学位を取得、同年より虎の門病院血液内科に赴任しました。現在は、血液内科全般と共に、移植後長期フォローアップ・予防接種外来を担当しています。

研究分野
移植後ウイルス感染症に関する研究からのスタートでしたが、現在は更に、移植後真菌感染症と、移植後の晩期合併症及び生活の質(Quality of Life: QOL)に関する臨床研究も行っています。移植後感染症については、主に、移植後中後期のウイルス感染症、移植後HHV-6ウイルス感染症、移植後VZV感染症、移植後真菌感染症をテーマにした研究を行っています。また、移植後の予防接種に関する研究も行っています。移植後長期合併症については、移植後の慢性移植片対宿主病(GVHD)に加えて、移植後骨合併症、移植後慢性腎臓病、二次がんなどに関する研究を行っています。これらは主に後方視的研究ですが、一方で移植後のQOLに関する前方視的な横断及び縦断調査研究も行っています。

今後の抱負
患者さんに近い立ち位置での研究がとても楽しく、現在も診療の傍らで臨床研究を続けています。治療を受けた患者さんが様々な合併症を克服し、極力QOLを維持した生活が送れるように、これらの領域の発展に役立つ臨床研究を、今後も継続していきたいと考えています。

発表・論文

発表・論文

1. Yuasa M, Yamamoto H, Kageyama K, Kaji D, Taya Y, Takagi S, Yamamoto G, Asano-Mori Y, Wake A, Yoneyama A, Makino S, Uchida N, Taniguchi S. Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation. Biol Blood Marrow Transplant. 2020;26(9):1689-96.

2. Uruga H, Sato T, Nishida A, Uchida N, Tsuji M, Moriguchi S, Takahashi Y, Ogawa K, Murase K, Hanada S, Takaya H, Miyamoto A, Morokawa N, Kimura M, Araoka H, Tsuchihashi R, Asano-Mori Y, Wake A, Taniguchi S, Kishi K. Safety of bronchoscopy in patients with malignant hematologic disorders. BMC Pulm Med. 2020;20(1):243.

3. Kurosawa S, Mori A, Tsukagoshi M, Onishi Y, Ohwada C, Mori T, Goto H, Asano-Mori Y, Nawa Y, Hino M, Fukuchi T, Mori Y, Yamahana R, Inamoto Y, Fukuda T. Current Status and Needs of Long-Term Follow-Up Clinics for Hematopoietic Cell Transplantation Survivors: Results of a Nationwide Survey in Japan. Biol Blood Marrow Transplant. 2020;26(5):949-55.

4. Kageyama K, Uchida N, Yamamoto H, Takagi S, Ebihara M, Yuasa M, Kaji D, Nishida A, Ishiwata K, Yamamoto G, Asano-Mori Y, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. HHV-6 associated diseases are one of the major factors on higher early CNS complications in CB recipients than in those of BM/PBSC. Bone Marrow Transplant. 2020.

5. Wada S, Asano-Mori Y, Yamamoto H, Yuasa M, Kageyama K, Kaji D, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Uchida N, Yoneyama A, Makino S, Taniguchi S. No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation. Bone Marrow Transplant. 2019;54(5):765-8.

6. Kimura M, Araoka H, Yamamoto H, Nakamura S, Nagi M, Yamagoe S, Miyazaki Y, Ogura S, Mitsuki T, Yuasa M, Kaji D, Kageyama K, Nishida A, Taya Y, Shimazu H, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Uchida N, Wake A, Taniguchi S, Yoneyama A. Micafungin Breakthrough Fungemia in Patients with Hematological Disorders. Antimicrob Agents Chemother. 2018;62(5).

7. Ota H, Yamamoto H, Kimura M, Araoka H, Fujii T, Umeyama T, Ohno H, Miyazaki Y, Kaji D, Taya Y, Nishida A, Ishiwata K, Tsuji M, Takagi S, Asano-Mori Y, Yamamoto G, Uchida N, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Successful Treatment of Pulmonary Mucormycosis Caused by Cunninghamella bertholletiae with High-Dose Liposomal Amphotericin B (10 mg/kg/day) Followed by a Lobectomy in Cord Blood Transplant Recipients. Mycopathologia. 2017;182(9-10):847-53.

8. Kimura M, Araoka H, Yamamoto H, Asano-Mori Y, Nakamura S, Yamagoe S, Ohno H, Miyazaki Y, Abe M, Yuasa M, Kaji D, Kageyama K, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Uchida N, Izutsu K, Wake A, Taniguchi S, Yoneyama A. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital. Antimicrob Agents Chemother. 2017;61(4).

9. Asano-Mori Y. Role of long-term follow-up in management of late-onset post-hematopoietic stem cell transplant complications. Rinsho Ketsueki. 2017;58(12):2450-60.

10. Asano-Mori Y. Diagnosis and Treatment of Mucormycosis in Patients withHematological MalignanciesTranslated Article. Med Mycol J. 2017;58(3):E97-E105.

11. Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. Biol Blood Marrow Transplant. 2016;22(10):1844-50.

12. Kimura M, Araoka H, Yoshida A, Yamamoto H, Abe M, Okamoto Y, Yuasa M, Kaji D, Kageyama K, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Uchida N, Hishinuma A, Izutsu K, Wake A, Taniguchi S, Yoneyama A. Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital. BMC Infect Dis. 2016;16:372.

13. Asano-Mori Y. Diagnosis and Treatment of Mucormycosis in Patients with Hematological Malignancies. Med Mycol J. 2016;57(4):J155-J62.

14. Asano-Mori Y. Prophylactic strategies for invasive fungal infections after allogeneic hematopoietic stem cell transplantation. Rinsho Ketsueki. 2016;57(10):2208-17.

15. Yamamoto H, Uchida N, Uchida Y, Nishida A, Ota H, Kageyama K, Nasu I, Wada S, Kaji D, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Matsuno N, Yamamoto G, Masuoka K, Izutsu K, Wake A, Yoneyama A, Makino S, Ito T, Hayashi M, Taniguchi S. Oral beclomethasone dipropionate as an initial treatment for stages 1-2 gastrointestinal tract acute graft-versus-host disease following unrelated cord blood transplantation. Ann Hematol. 2015;94(12):2073-5.

16. Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, Ikebe T, Nakano N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone Marrow Transplant. 2015;50(4):607-9.

17. Watanabe M, Kaji D, Hashimoto-Maeda M, Yamamoto G, Asano-Mori Y, Uchida N, Taniguchi S, Izutsu K. [Subacute encephalopathy after high-dose methotrexate as prophylaxis for central nervous system relapse in a patient with intravascular large B-cell lymphoma]. Rinsho Ketsueki. 2015;56(3):329-34.

18. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015;21(11):2008-16.

19. Yuasa M, Ishiwata K, Sugio T, Kaji D, Ota H, Tsuji M, Yamamoto H, Yamamoto G, Asano-Mori Y, Uchida N, Izutsu K, Taniguchi S. [Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid leukemia]. Rinsho Ketsueki. 2014;55(6):682-6.

20. Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. Biol Blood Marrow Transplant. 2014;20(10):1634-40.

21. Takagi S, Araoka H, Uchida N, Uchida Y, Kaji D, Ota H, Nishida A, Ishiwata K, Tsuji M, Yamamoto H, Ito T, Matsuno N, Yamamoto G, Asano-Mori Y, Hayashi M, Izutsu K, Masuoka K, Wake A, Makino S, Yoneyama A, Taniguchi S. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. Int J Hematol. 2014;99(5):652-8.

22. Hosokawa K, Takami A, Tsuji M, Araoka H, Ishiwata K, Takagi S, Yamamoto H, Asano-Mori Y, Matsuno N, Uchida N, Masuoka K, Wake A, Makino S, Yoneyama A, Nakao S, Taniguchi S. Relative incidences and outcomes of Clostridium difficile infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. Transpl Infect Dis. 2014;16(3):412-20.

23. Matsuno N, Yamamoto H, Watanabe N, Uchida N, Ota H, Nishida A, Ikebe T, Ishiwata K, Nakano N, Tsuji M, Asano-Mori Y, Izutsu K, Masuoka K, Wake A, Yoneyama A, Nakauchi H, Taniguchi S. Rapid T-cell chimerism switch and memory T-cell expansion are associated with pre-engraftment immune reaction early after cord blood transplantation. Br J Haematol. 2013;160(2):255-8.

24. Oshima K, Takahashi W, Asano-Mori Y, Izutsu K, Takahashi T, Arai Y, Nakagawa Y, Usuki K, Kurokawa M, Suzuki K, Mitani K, Kanda Y. Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS). Ann Hematol. 2012;91(10):1533-9.

25. Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K, Nakano N, Tsuji M, Yamamoto H, Asano-Mori Y, Uchida N, Wake A, Taniguchi S, Yoneyama A. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012;14(4):355-63.

26. Yamamoto H, Kato D, Uchida N, Ishiwata K, Araoka H, Takagi S, Nakano N, Tsuji M, Asano-Mori Y, Matsuno N, Masuoka K, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood. 2011;117(11):3240-2.

27. Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, Yamamoto H, Kato D, Matsuno N, Masuoka K, Araoka H, Asano-Mori Y, Izutsu K, Makino S, Yoneyama A, Taniguchi S. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation. 2011;92(3):366-71.

28. Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010;116(4):649-52.

29. Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, Nakahara F, Okamoto S, Kurokawa M, Kanda Y. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis. 2010;12(5):421-7.

30. Asano-Mori Y. Fungal infections after hematopoietic stem cell transplantation. Int J Hematol. 2010;91(4):576-87.

31. Araoka H, Baba M, Takagi S, Matsuno N, Ishiwata K, Nakano N, Tsuji M, Yamamoto H, Seo S, Asano-Mori Y, Uchida N, Masuoka K, Wake A, Taniguchi S, Yoneyama A. Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'. Scand J Infect Dis. 2010;42(3):231-3.

32. Oshima K, Kanda Y, Kako S, Asano-Mori Y, Watanabe T, Motokura T, Chiba S, Shiraki K, Kurokawa M. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol. 2008;80(10):1769-75.

33. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83(6):472-6.

34. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol. 2008;87(3):310-8.

35. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Kaneko M, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2008;61(2):411-6.

36. Oshima K, Kanda Y, Asano-Mori Y, Nishimoto N, Arai S, Nagai S, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2007;60(2):350-5.

37. Asano-Mori Y, Kanda Y, Oshima K, Watanabe T, Shoda E, Motokura T, Kurokawa M, Chiba S. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother. 2006;57(5):1004-7.

38. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, Izutsu K, Watanabe T, Shoda E, Ogawa S, Motokura T, Chiba S, Kurokawa M, Hirai H, Kanda Y. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant. 2005;36(9):821-4.

39. Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, Izutsu K, Hangaishi A, Tsujino S, Ogawa S, Motokura T, Chiba S, Hirai H. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation. 2005;79(10):1351-7.

40. Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M, Oshima K, Isayama H, Ogawa S, Motokura T, Chiba S, Ohtomo K, Omata M, Hirai H. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation. 2005;79(7):821-7.

41. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, Nakagawa M, Kandabashi K, Izutsu K, Hangaishi A, Motokura T, Chiba S, Kurokawa M, Hirai H, Kanda Y. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(9):813-9.

42. Sakata-Yanagimoto M, Kanda Y, Nakagawa M, Asano-Mori Y, Kandabashi K, Izutsu K, Imai Y, Hangaishi A, Kurokawa M, Tsujino S, Ogawa S, Chiba S, Motokura T, Hirai H. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33(10):1043-7.

43. Asano Y, Kanda Y, Ogawa N, Sakata-Yanagimoto M, Nakagawa M, Kawazu M, Goyama S, Kandabashi K, Izutsu K, Imai Y, Hangaishi A, Kurokawa M, Tsujino S, Ogawa S, Aoki K, Chiba S, Motokura T, Hirai H. Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32(12):1175-9

Copyright © 2020 冲中記念成人病研究所 All Rights Reserved.